Hers vs Medvi: Two Compounded GLP-1 Telehealth Routes Compared

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Picking between two online weight-management brands rarely turns on the marketing and almost always turns on the plumbing behind it. This PlexusDx Education Hub review places Hers and Medvi side by side, works through how each is built, and closes on a biological factor that sits outside both. Browse all Peptides & GLP-1 education.

Full head-to-head: PlexusDx vs MEDVi →

Editorial independence note: PlexusDx produced this comparison with no commercial arrangement, affiliate link, or referral fee tied to Hers, Medvi, or their parent organizations. Nothing here is sponsored.

Hers and Medvi are two names in a field of dozens of telehealth GLP-1 programs. Both lean on compounding pharmacies to dispense, which makes them a useful pair to examine together. The sections that follow trace each brand's structure, the 503A route they share, the levers that move the monthly bill, and the genetic context neither one measures. Market details reflect public information as of April 2026.

How Hers is built

Hers sits inside Hims & Hers Health and runs on a subscription-telehealth model. A prospective patient completes an online evaluation, a licensed clinician reviews it, and, when appropriate, a prescription is issued for either an FDA-approved brand GLP-1 or a compounded semaglutide or tirzepatide prepared by a licensed compounding pharmacy. Current program specifics live on Hers's official website.

How Medvi is built

Medvi Wellness operates as a telehealth service paired with compounded-pharmacy fulfillment. Its medication menu, membership terms, and totals shift over time, so the authoritative source is Medvi's official website at the moment you evaluate it rather than any third-party summary.

The 503A compounded route both lean on

Because both brands can route prescriptions to compounding pharmacies, it helps to understand what that means. A 503A compounding pharmacy prepares a medication for an individual patient against a valid prescription. The active molecule in a compounded semaglutide or tirzepatide belongs to the same pharmacologic family as the branded version, but the preparation, concentration, and presentation can differ. That is where two programs on the same route can still feel different to a patient.

Where the pharmacology is actually decided

Whatever the brand on the box, GLP-1 receptor agonists such as semaglutide, liraglutide, and dulaglutide, along with the GIP/GLP-1 dual agonist tirzepatide, act on appetite signaling, satiety, and the rate at which the stomach empties. That biology is a property of the compound, not the platform prescribing it. What genuinely varies between Hers and Medvi is the business model, whether dispensing runs through a retail or compounding channel, the depth of clinical follow-up, and price.

What drives the monthly figure

Across online GLP-1 programs, total monthly spend as of April 2026 tends to land somewhere in a broad band of roughly $200 to $700 or more, shaped by the specific compound, the subscription commitment, and dispensing fees. Rather than quote a number that may already be out of date, confirm each brand's live pricing on its own page before committing. The cost drivers matter more than any single figure: molecule chosen, prepay length, and what the fee actually bundles.

The evidence behind the compounds

The molecule class carries a substantial trial record. Semaglutide was studied for weight management in the STEP program (New England Journal of Medicine, 2021); tirzepatide in SURMOUNT (NEJM, 2022); and tirzepatide again for obstructive sleep apnea in SURMOUNT-OSA (NEJM, 2024). Endpoints, doses, and populations differ across these programs, and individual results are never guaranteed by trial averages.

The genetic layer neither program maps

What Hers and Medvi both leave untouched is the inherited biology a GLP-1 acts upon. A variant in FTO, the fat-mass and obesity-associated gene, along with GLP1R (the receptor every GLP-1 compound targets), MC4R (central to satiety and energy balance), and TCF7L2 (tied to glucose handling), describes the metabolic starting point a clinician prescribes into. These are pathway-level markers. They do not forecast how you will respond to a particular drug, but they sketch the terrain.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols, available as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. The difference is what comes first: the Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights, including FTO, MC4R, and TCF7L2, so you and your provider start a protocol with context rather than a blank slate. Test before you invest.

Not affiliated: PlexusDx has no relationship with Hers or Medvi and reviewed both independently.

Related reading on PlexusDx: GLP 1 What Is, GLP 1 Receptor Agonist, GLP 1 Drugs, GLP 1 Hormone.

Disclaimer: This article is educational. PlexusDx is not affiliated with Hers or Medvi and has no commercial relationship with the companies reviewed. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways and does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

See the PlexusDx approach: explore the Weight Management Protocols, or start upstream with the Precision Peptide Genetic Test.

Frequently Asked Questions

Do Hers and Medvi use the same pharmacies?

Not necessarily. Both can route compounded prescriptions through licensed 503A compounding pharmacies, but each brand contracts its own partners, and details change. The pharmacy network, oversight, and fulfillment logistics are published on each brand's site, so confirm current arrangements there rather than assuming the two overlap.

Why does compounded pricing vary so much between them?

Compounded GLP-1 pricing reflects the molecule, the prepay term, and what the subscription bundles, such as supplies, shipping, and follow-up. Two programs on the same 503A route can still price differently because those variables differ. Compare the full bundle rather than a single headline figure when weighing Hers against Medvi.

Does the Precision Peptide Genetic Test tell me which brand to pick?

No. The test does not predict response to a compound or endorse a telehealth brand. It maps pathway-level variants in FTO and MC4R, and TCF7L2 that describe your baseline GLP-1 biology, giving you context that applies no matter which program ultimately dispenses your prescription.

Where does PlexusDx fit alongside these two?

PlexusDx dispenses semaglutide and tirzepatide through its Weight Management Protocols and pairs them with upstream genetic context via the Precision Peptide Genetic Test. That pathway-level insight into FTO, MC4R is the layer that neither Hers nor Medvi builds into its offering.

Continue in the Education Hub. Browse all Peptides & GLP-1 education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.